Full Description
Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.
With over 35 new FDA-approved indications since the second edition—featuring groundbreaking advancements such as CAR-T therapy—this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.
Key Features:
New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.
Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.
Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.
Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.
Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.
Contents
Contributors
Preface
Abbreviations
PART I. INTRODUCTION AND OVERVIEW
1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses
2. ICC and WHO Classifications and Potential Future Harmonization
3. Familial/Inherited Variants and Risks of Hematologic Malignancies
4. Diagnostic Approaches to Hematologic Malignancies
5. Minimal Residual Disease Assays
6. Personalized Approach to Hematologic Malignancies
PART II. MYELOPROLIFERATIVE NEOPLASMS
7. Polycythemia Vera
8. Essential Thrombocythemia
9. Primary Myelofibrosis
10. Chronic Myelogenous Leukemia
11. Chronic Neutrophilic Leukemia
12. Systemic Mastocytosis
13. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion (MLN-TK)
PART III. MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES
14. CHIP, CCUS and Precursor States of Myeloid Neoplasms
15. Myelodysplastic Syndromes
16. Aplastic Anemia
17. Paroxysmal Nocturnal Hemoglobinuria
PART IV. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS
18. Myelodysplastic/Myeloproliferative Neoplasms
19. Chronic Myelomonocytic Leukemia
PART V. ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES
20. Acute Myeloid Leukemia
21. Secondary AML and AML-MRC
22. Acute Promyelocytic Leukemia
23. Blastic Plasmacytoid Dendritic Cell Neoplasm
PART VI. ACUTE LYMPHOID LEUKEMIA
24. B-Lymphoblastic Leukemia/Lymphoma
25. BCR-ABL1+ B-Lymphoblastic Leukemia
26. T-Cell Acute Lymphoblastic Leukemia/Lymphoma
PART VII. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
27. Acute Leukemia of Ambiguous Lineage
PART VIII. MATURE T- AND NK-CELL LEUKEMIA
28. T-Cell Prolymphocytic Leukemia
29. T-Cell Large Granular Lymphocytic Leukemia
30. Aggressive Natural Killer Cell Leukemia
PART IX. PLASMA CELL DISORDERS
31. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas
32. Multiple Myeloma
33. Waldenström Macroglobulinemia
34. Immunoglobulin Light Chain Amyloidosis AL
PART X. HODGKIN LYMPHOMA
35. Hodgkin Lymphoma
PART XI. NON-HODGKIN LYMPHOMA
36. Diagnosis and Classification of Non-Hodgkin Lymphomas
PART XII. MATURE B-CELL LYMPHOMA
VERY AGGRESIVE
37. Burkitt Lymphoma
AGGRESSIVE
38. Diffuse Large B-Cell Lymphoma
39. Double-Hit Lymphoma
40. Mantle Cell Lymphoma
41. Primary Central Nervous System Lymphoma
42. HIV-Related Lymphomas
43. Follicular Lymphoma
44. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
45. Hairy Cell Leukemia
46. Marginal Zone Lymphoma
PART XIII. MATURE T- AND NK-CELL LYMPHOMA
47. Peripheral T-Cell Lyphoma
48. Adult T-Cell Leukemia/Lymphoma
49. Anaplastic Large Cell Lymphoma
50. Extranodal Natural Killer/T-Cell Lymphoma
51. Mycosis Fungoides/Sézary Syndrome
52. Hepatosplenic T-Cell Lymphoma
PART XIV. HISTIOCYTIC/DENDRITIC CELL NEOPLASMS
53. Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Histiocytic Sarcoma
54. Hemophagocytic Lymphohistiocytosis
PART XV. BONE MARROW TRANSPLANTATION
55. Autologous Hematopoietic Cell Transplantation
56. Allogeneic Hematopoietic Cell Transplantation
PART XVI. NEW CELLULAR IMMUNOTHERAPY
57. CAR-T Overview and Novel Cellular Therapeutic Options
58. CD19 CAR T-Cell Therapy
59. BCMA CAR T-Cell Therapy
60. Cytokine Release Syndrome and Other Toxicities Associated With Cellular Therapies
PART XVII. EMERGENCIES IN HEMATOLOGY
61. Cancer-Associated Thrombosis in Hematologic Malignancies
62. Tumor Lysis Syndrome
63. Thrombotic Microangiopathy
64. Therapeutic Apheresis Indications
Appendix: Pathology Supplement
Index
